Cargando…
Metabolic features of cancer cells impact immunosurveillance
BACKGROUND: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upre...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231002/ https://www.ncbi.nlm.nih.gov/pubmed/34162714 http://dx.doi.org/10.1136/jitc-2021-002362 |
_version_ | 1783713334921527296 |
---|---|
author | Joseph, Adrien Juncheng, Pan Mondini, Michele Labaied, Nizar Loi, Mauro Adam, Julien Lafarge, Antoine Astesana, Valentina Obrist, Florine Klein, Christophe Bloy, Norma Stoll, Gautier Signolle, Nicolas Genestie, Catherine Damotte, Diane Alifano, Marco Leary, Alexandra Pautier, Patricia Morice, Philippe Gouy, Sebastien Deutsch, Eric Chargari, Cyrus Dieu-Nosjean, Marie-Caroline Cremer, Isabelle Michels, Judith Kroemer, Guido Castedo, Maria |
author_facet | Joseph, Adrien Juncheng, Pan Mondini, Michele Labaied, Nizar Loi, Mauro Adam, Julien Lafarge, Antoine Astesana, Valentina Obrist, Florine Klein, Christophe Bloy, Norma Stoll, Gautier Signolle, Nicolas Genestie, Catherine Damotte, Diane Alifano, Marco Leary, Alexandra Pautier, Patricia Morice, Philippe Gouy, Sebastien Deutsch, Eric Chargari, Cyrus Dieu-Nosjean, Marie-Caroline Cremer, Isabelle Michels, Judith Kroemer, Guido Castedo, Maria |
author_sort | Joseph, Adrien |
collection | PubMed |
description | BACKGROUND: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types. METHODS: Tumors from patients with locally advanced cervical carcinoma (LACC) and non-small cell lung cancer (NSCLC) were stained for PAR, PDXK, dendritic cell lysosomal associated membrane glycoprotein (DC-LAMP) and CD8 T cell infiltration. Their correlations and prognostic impact were assessed. Cisplatin-resistant NSCLC cell clones isolated from Lewis-lung cancer (LLC) cells were evaluated for PAR levels by immunoblot. Parental (PAR(low)) and cisplatin-resistant (PAR(high)) clones were subcutaneously injected into the flank of C57BL/6 mice. Tumors were harvested to evaluate their immune infiltration by flow cytometry. RESULTS: The infiltration of tumors by CD8 T and DC-LAMP(+) cells was associated with a favorable overall survival in patients with LACC (p=0.006 and p=0.008, respectively) and NSCLC (p<0.001 for both CD8 T and DC-LAMP cells). We observed a positive correlation between PDXK expression and the infiltration by DC-LAMP (R=0.44, p=0.02 in LACC, R=0.14, p=0.057 in NSCLC), and a negative correlation between PAR levels and CD8 T lymphocytes (R=−0.39, p=0.034 in LACC, R=−0.18, p=0.017 in NSCLC). PARP1 is constitutively hyperactivated in cisplatin-resistant LLC cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PAR(high)). Tumors formed by such cancer cells injected into immunocompetent mice were scarcely infiltrated by CD8 T (p=0.028) and antigen presenting cells (p=0.086). CONCLUSIONS: Oncometabolic features can impact local immunosurveillance, providing new functional links between cisplatin resistance and therapeutic failure. |
format | Online Article Text |
id | pubmed-8231002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82310022021-07-09 Metabolic features of cancer cells impact immunosurveillance Joseph, Adrien Juncheng, Pan Mondini, Michele Labaied, Nizar Loi, Mauro Adam, Julien Lafarge, Antoine Astesana, Valentina Obrist, Florine Klein, Christophe Bloy, Norma Stoll, Gautier Signolle, Nicolas Genestie, Catherine Damotte, Diane Alifano, Marco Leary, Alexandra Pautier, Patricia Morice, Philippe Gouy, Sebastien Deutsch, Eric Chargari, Cyrus Dieu-Nosjean, Marie-Caroline Cremer, Isabelle Michels, Judith Kroemer, Guido Castedo, Maria J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types. METHODS: Tumors from patients with locally advanced cervical carcinoma (LACC) and non-small cell lung cancer (NSCLC) were stained for PAR, PDXK, dendritic cell lysosomal associated membrane glycoprotein (DC-LAMP) and CD8 T cell infiltration. Their correlations and prognostic impact were assessed. Cisplatin-resistant NSCLC cell clones isolated from Lewis-lung cancer (LLC) cells were evaluated for PAR levels by immunoblot. Parental (PAR(low)) and cisplatin-resistant (PAR(high)) clones were subcutaneously injected into the flank of C57BL/6 mice. Tumors were harvested to evaluate their immune infiltration by flow cytometry. RESULTS: The infiltration of tumors by CD8 T and DC-LAMP(+) cells was associated with a favorable overall survival in patients with LACC (p=0.006 and p=0.008, respectively) and NSCLC (p<0.001 for both CD8 T and DC-LAMP cells). We observed a positive correlation between PDXK expression and the infiltration by DC-LAMP (R=0.44, p=0.02 in LACC, R=0.14, p=0.057 in NSCLC), and a negative correlation between PAR levels and CD8 T lymphocytes (R=−0.39, p=0.034 in LACC, R=−0.18, p=0.017 in NSCLC). PARP1 is constitutively hyperactivated in cisplatin-resistant LLC cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PAR(high)). Tumors formed by such cancer cells injected into immunocompetent mice were scarcely infiltrated by CD8 T (p=0.028) and antigen presenting cells (p=0.086). CONCLUSIONS: Oncometabolic features can impact local immunosurveillance, providing new functional links between cisplatin resistance and therapeutic failure. BMJ Publishing Group 2021-06-23 /pmc/articles/PMC8231002/ /pubmed/34162714 http://dx.doi.org/10.1136/jitc-2021-002362 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Immunotherapy Biomarkers Joseph, Adrien Juncheng, Pan Mondini, Michele Labaied, Nizar Loi, Mauro Adam, Julien Lafarge, Antoine Astesana, Valentina Obrist, Florine Klein, Christophe Bloy, Norma Stoll, Gautier Signolle, Nicolas Genestie, Catherine Damotte, Diane Alifano, Marco Leary, Alexandra Pautier, Patricia Morice, Philippe Gouy, Sebastien Deutsch, Eric Chargari, Cyrus Dieu-Nosjean, Marie-Caroline Cremer, Isabelle Michels, Judith Kroemer, Guido Castedo, Maria Metabolic features of cancer cells impact immunosurveillance |
title | Metabolic features of cancer cells impact immunosurveillance |
title_full | Metabolic features of cancer cells impact immunosurveillance |
title_fullStr | Metabolic features of cancer cells impact immunosurveillance |
title_full_unstemmed | Metabolic features of cancer cells impact immunosurveillance |
title_short | Metabolic features of cancer cells impact immunosurveillance |
title_sort | metabolic features of cancer cells impact immunosurveillance |
topic | Immunotherapy Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231002/ https://www.ncbi.nlm.nih.gov/pubmed/34162714 http://dx.doi.org/10.1136/jitc-2021-002362 |
work_keys_str_mv | AT josephadrien metabolicfeaturesofcancercellsimpactimmunosurveillance AT junchengpan metabolicfeaturesofcancercellsimpactimmunosurveillance AT mondinimichele metabolicfeaturesofcancercellsimpactimmunosurveillance AT labaiednizar metabolicfeaturesofcancercellsimpactimmunosurveillance AT loimauro metabolicfeaturesofcancercellsimpactimmunosurveillance AT adamjulien metabolicfeaturesofcancercellsimpactimmunosurveillance AT lafargeantoine metabolicfeaturesofcancercellsimpactimmunosurveillance AT astesanavalentina metabolicfeaturesofcancercellsimpactimmunosurveillance AT obristflorine metabolicfeaturesofcancercellsimpactimmunosurveillance AT kleinchristophe metabolicfeaturesofcancercellsimpactimmunosurveillance AT bloynorma metabolicfeaturesofcancercellsimpactimmunosurveillance AT stollgautier metabolicfeaturesofcancercellsimpactimmunosurveillance AT signollenicolas metabolicfeaturesofcancercellsimpactimmunosurveillance AT genestiecatherine metabolicfeaturesofcancercellsimpactimmunosurveillance AT damottediane metabolicfeaturesofcancercellsimpactimmunosurveillance AT alifanomarco metabolicfeaturesofcancercellsimpactimmunosurveillance AT learyalexandra metabolicfeaturesofcancercellsimpactimmunosurveillance AT pautierpatricia metabolicfeaturesofcancercellsimpactimmunosurveillance AT moricephilippe metabolicfeaturesofcancercellsimpactimmunosurveillance AT gouysebastien metabolicfeaturesofcancercellsimpactimmunosurveillance AT deutscheric metabolicfeaturesofcancercellsimpactimmunosurveillance AT chargaricyrus metabolicfeaturesofcancercellsimpactimmunosurveillance AT dieunosjeanmariecaroline metabolicfeaturesofcancercellsimpactimmunosurveillance AT cremerisabelle metabolicfeaturesofcancercellsimpactimmunosurveillance AT michelsjudith metabolicfeaturesofcancercellsimpactimmunosurveillance AT kroemerguido metabolicfeaturesofcancercellsimpactimmunosurveillance AT castedomaria metabolicfeaturesofcancercellsimpactimmunosurveillance |